Does Blue Cross Blue Shield Cover Farxiga?

How BCBS Formularies Classify Farxiga

Blue Cross Blue Shield is not a single insurer. It is a federation of 34 independent companies operating across all 50 states, and each company maintains its own formulary. That structural detail matters because a member in Illinois may face different tier placement, cost-sharing, and prior authorization criteria than a member in Florida, even when both carry "BCBS" on their card.

Across most BCBS affiliates, Farxiga (dapagliflozin) appears on the formulary as a Tier 2 preferred brand or Tier 3 non-preferred brand drug [1]. Tier placement determines your copay or coinsurance percentage. A Tier 2 listing generally means a fixed copay between $30 and $75 per fill, while Tier 3 placement may involve 25% to 40% coinsurance on a list price near $600, translating to $145 to $240 before any manufacturer offset [2].

The FDA approved dapagliflozin for three distinct indications: type 2 diabetes mellitus, heart failure with reduced or preserved ejection fraction, and chronic kidney disease with an eGFR of 25 to 75 mL/min/1.73 m² [3]. The indication your prescriber writes on the prior authorization form can shift whether Farxiga lands on a preferred or restricted tier within the same plan.

Some BCBS affiliates have moved SGLT2 inhibitors to preferred status after the 2022 ADA Standards of Care update recommended SGLT2 inhibitors independent of A1C for patients with established atherosclerotic cardiovascular disease, heart failure, or CKD [4]. If your plan has not yet reflected this guideline shift, that disconnect becomes a strong basis for appeal.

What Prior Authorization Involves

Prior authorization is standard for Farxiga across BCBS plans. Expect it. The process typically requires your prescriber to submit documentation confirming the diagnosis, prior medication trials, and clinical justification.

For the type 2 diabetes indication, most BCBS affiliates require evidence that the patient has tried or cannot tolerate metformin. This is called step therapy. The American Diabetes Association's 2024 Standards of Care recommend SGLT2 inhibitors as first-line add-on therapy (or in select cases, first-line alongside metformin) for patients with type 2 diabetes and cardiorenal comorbidities [4]. Citing this guideline specifically in the prior authorization letter strengthens the case.

For heart failure, the prior authorization criteria are often less restrictive. The DAPA-HF trial (N=4,744) demonstrated a 26% relative risk reduction in the composite of worsening heart failure or cardiovascular death with dapagliflozin versus placebo (HR 0.74 to 95% CI 0.65 to 0.85, P<0.001) [5]. The American College of Cardiology and American Heart Association 2022 heart failure guidelines list SGLT2 inhibitors as a Class I recommendation for heart failure regardless of ejection fraction [6]. Quoting this recommendation verbatim in the prior authorization request can accelerate approval.

For the CKD indication, the DAPA-CKD trial (N=4,304) showed a 39% relative risk reduction in the composite of sustained decline in eGFR of at least 50%, end-stage kidney disease, or death from renal or cardiovascular causes (HR 0.61 to 95% CI 0.51 to 0.72, P<0.001) [7]. KDIGO 2024 guidelines recommend dapagliflozin for patients with CKD and an eGFR of 20 to 45 mL/min/1.73 m², regardless of diabetes status [8]. This indication often receives faster prior authorization approval because the evidence base is unambiguous and the alternative treatment options are limited.

The entire prior authorization process usually takes 48 to 72 hours when submitted electronically. Paper submissions may take 5 to 10 business days.

Farxiga Cost Breakdown With BCBS Insurance

The out-of-pocket cost for Farxiga under a BCBS plan depends on four variables: formulary tier, plan type (HMO, PPO, HDHP), deductible status, and whether you have met your annual out-of-pocket maximum.

Before the deductible is met on a high-deductible health plan, you pay the negotiated rate, which typically falls between $480 and $580 for a 30-day supply of dapagliflozin 10 mg. After meeting the deductible, cost-sharing kicks in. On a Tier 2 plan, expect $30 to $75 per fill. On a Tier 3 plan, expect $90 to $150 or coinsurance of 25% to 40%.

Dr. Robert Gabbay, Chief Scientific and Medical Officer at the American Diabetes Association, has stated: "Cost remains one of the most significant barriers to patients accessing medications that have proven cardiovascular and renal benefits beyond glucose lowering" [9]. This observation applies directly to SGLT2 inhibitors like Farxiga, where the list price creates friction even for insured patients.

Medicare Advantage BCBS plans follow a separate formulary structure. Under Medicare Part D, dapagliflozin typically falls on Tier 3 (preferred brand) with a copay of $42 to $100 during the initial coverage phase. After entering the coverage gap, the Inflation Reduction Act caps insulin at $35 monthly but does not specifically cap SGLT2 inhibitor costs. The $2,000 annual out-of-pocket maximum under the Inflation Reduction Act (effective 2025) does provide a ceiling for total Part D spending, which benefits patients taking multiple brand-name medications [10].

For commercially insured BCBS members, AstraZeneca's Farxiga Savings Card can reduce the copay to as low as $0 per month, with a maximum annual benefit. Eligibility requires commercial insurance. Medicare, Medicaid, and Tricare beneficiaries are excluded from manufacturer savings cards by federal anti-kickback statute.

What Happens If BCBS Denies Coverage

A denial is not the end. BCBS plans are required by federal and state law to provide a formal appeals process. The Affordable Care Act mandates both internal and external review for coverage denials on all non-grandfathered plans [11].

The first step after denial is an internal appeal. Your prescriber should submit a letter of medical necessity that includes: the specific diagnosis and ICD-10 code, the clinical rationale for dapagliflozin over alternatives, any prior medication trials and outcomes, and citations to current guideline recommendations. Reference the ADA Standards of Care, ACC/AHA heart failure guidelines, or KDIGO CKD guidelines depending on the indication [4][6][8].

If the internal appeal is denied, request an external review. An independent review organization (IRO) evaluates the case using evidence-based criteria. External reviews overturn internal denials in a meaningful percentage of cases, particularly when the prescriber cites Level A evidence from randomized controlled trials.

During the appeal window, ask your prescriber about a 72-hour urgent or expedited authorization if the medication is clinically time-sensitive, such as for a patient with rapidly declining eGFR or acute decompensated heart failure.

A peer-to-peer review is another option. Your prescriber can speak directly with the BCBS medical director to discuss the clinical rationale. These conversations often resolve denials faster than written appeals alone. Dr. Mikhail Kosiborod, Director of Cardiometabolic Research at Saint Luke's Mid America Heart Institute, has noted: "The evidence supporting SGLT2 inhibitors for heart failure and CKD is among the strongest in modern cardiovascular medicine, and payer policies should reflect that evidence" [12].

How Farxiga Compares to Covered Alternatives

When BCBS denies or restricts Farxiga, the plan may suggest an alternative SGLT2 inhibitor. Jardiance (empagliflozin) is the most common therapeutic substitute and holds similar FDA approvals for type 2 diabetes, heart failure, and CKD. On many BCBS formularies, Jardiance and Farxiga occupy the same tier. Occasionally, one is preferred over the other based on the rebate agreement between the BCBS affiliate and the manufacturer.

In the DECLARE-TIMI 58 trial (N=17,160), dapagliflozin reduced hospitalization for heart failure by 27% versus placebo in patients with type 2 diabetes (HR 0.73 to 95% CI 0.61 to 0.88) [13]. The EMPA-REG OUTCOME trial (N=7,020) demonstrated a 35% relative risk reduction in hospitalization for heart failure with empagliflozin (HR 0.65 to 95% CI 0.50 to 0.85) [14]. Direct head-to-head trials between dapagliflozin and empagliflozin do not exist, so treatment selection is guided by formulary access, tolerability, and prescriber preference rather than superiority data.

Invokana (canagliflozin) is another SGLT2 inhibitor but carries a boxed warning for increased amputation risk based on the CANVAS trial [15]. This safety signal makes it a less attractive substitute for most prescribers. Steglatro (ertugliflozin) is a fourth option with more limited outcome data.

If no SGLT2 inhibitor is covered at an acceptable cost, GLP-1 receptor agonists represent an alternative class with overlapping cardiorenal benefits. Semaglutide (Ozempic) and dulaglutide (Trulicity) have demonstrated cardiovascular risk reduction in large outcome trials [16]. The drug classes work through different mechanisms and are sometimes prescribed together for additive benefit.

Specific BCBS Affiliate Variations

Coverage policies vary across BCBS affiliates. A few examples illustrate the range.

Anthem Blue Cross (California, several other states) lists Farxiga on Tier 3 for most commercial plans. Prior authorization requires documented metformin use for the diabetes indication. The heart failure and CKD indications require documentation of the specific FDA-approved condition and relevant lab values (ejection fraction for HF, eGFR for CKD).

Blue Cross Blue Shield of Michigan places Farxiga on the preferred brand tier for select PPO plans but requires prior authorization across all plan types. Step therapy through metformin is enforced for the diabetes indication.

Highmark BCBS (Pennsylvania, West Virginia, Delaware) lists Farxiga as a non-preferred brand on several plan designs. Members may face coinsurance rather than a flat copay, increasing monthly cost to $120 to $200 before manufacturer savings card application.

CareFirst BCBS (Maryland, DC, Virginia) has moved SGLT2 inhibitors to preferred brand status for patients with documented heart failure or CKD, reflecting the guideline-driven shift in clinical practice.

The fastest way to verify your specific plan's coverage is to call the member services number on the back of your BCBS card and ask three questions: Is dapagliflozin on my formulary? What tier? Does it require prior authorization or step therapy?

How to Lower Your Out-of-Pocket Cost

Several strategies can reduce the monthly cost of Farxiga under BCBS coverage.

Apply the AstraZeneca Farxiga Savings Card. Commercially insured patients may pay $0 per fill, subject to annual limits. The card stacks on top of BCBS coverage, meaning it applies after your plan processes the claim. Check the AstraZeneca website for current terms.

Ask about 90-day mail-order fills. Many BCBS plans offer lower per-unit pricing for 90-day supplies through their preferred mail-order pharmacy. The copay for a 90-day fill is often 2 to 2.5 times the 30-day copay rather than 3 times, saving roughly $30 to $75 per quarter.

Request a formulary exception. If your plan covers Jardiance at a lower tier but your prescriber prefers Farxiga for a specific clinical reason (such as the CKD indication data from DAPA-CKD), a formulary exception request can sometimes move Farxiga to the lower tier's cost-sharing.

Explore patient assistance programs. AstraZeneca's AZ&Me program provides Farxiga at no cost for patients who are uninsured or underinsured and meet income eligibility criteria (generally household income at or below 400% of the federal poverty level) [17].

Use an independent copay assistance foundation. Organizations like the Patient Access Network Foundation and the HealthWell Foundation periodically open funds for SGLT2 inhibitor copay assistance [18]. Fund availability fluctuates, so check quarterly.

A pharmacy benefits consultant or patient advocate at your prescriber's office can coordinate these options. The combined effect of manufacturer savings, formulary exceptions, and mail-order pricing often brings the monthly out-of-pocket below $30 for commercially insured BCBS members.